english.prescrire.org > Spotlight > 100 most recent > Weekly methotrexate: evaluation of risk minimisation measures commissioned by the European Medicines Agency

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Weekly methotrexate: evaluation of risk minimisation measures commissioned by the European Medicines Agency

 Outlook  The European Medicines Agency (EMA) recently commissioned a private company to evaluate the "risk minimisation measures" it has introduced to reduce errors related to taking or injecting methotrexate at daily instead of weekly intervals. The impact of these measures was found to be modest at best. 
Full article available for download by subscribers

 ©Prescrire 1 December 2025

Source: "Weekly methotrexate: evaluation of risk minimisation measures commissioned by the European Medicines Agency" Prescrire Int 2025; 34 (276): 305-307. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:

"Weekly methotrexate:
welcome measures
to prevent fatal errors"
Prescrire Int 2020;
29 (216): 154-155.